Monday, June 30, 2025 6/30/2025

Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease

Award Number: R44NS084565
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2014
PERIOD OF PERFORMANCE END DATE: 08/31/2022

Group Awards By:

View Award Description

Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease - The goal of this SBIR proposal is to develop an effective enzyme replacement therapy (ERT) for patients suffering from GM1 Gangliosidosis by applying a novel ERT enzyme-lectin fusion delivery strategy developed at BioStrategies LC and by exploiting safety, supply, and cost advantages of a plant-based ERT protein bio-manufacturing system. GM1 Gangliosidosis is a rare lysosomal disease affecting less than 200,000 people in the U.S. It is caused by a defect in the gene encoding the enzyme β-galactosidase and is characterized by progressive degeneration of normal childhood development especially in brain function leading to death at an early age. Current treatment options are limited to management of disease symptoms and development of an effective ERT drug has been hindered by challenges of delivering these drugs across the blood brain barrier to the brain and central nervous system. This research project is a collaboration between BioStrategies LC, a company focused on doing innovative research in lysosomal disease ERT development, and St. Jude Children’s Research Hospital, an international center for GM1 Gangliosidosis research. This SBIR Phase II is designed to lead to an effective ERT treatment for GM1 Gangliosidosis patients, a patient population with desperate need for new therapeutic options. In Phase I we met project goals by showing that a plant-produced ERT consisting of a fusion between human β-gal and the plant RTB lectin could be delivered into lysosomes of human disease cells where it reduced the pathogenic levels of GM1 substrate to normal. Follow up animal studies in the GM1 disease mouse model showed that this ERT complex was effective in delivering active enzyme to tissues of both visceral organs and the CNS producing a significant reduction in the high levels of GM1 enzyme substrate associated with the GM1 disease phenotype. These results raise the hope that this novel plant lectin-ERT fusion cell delivery technology could lead to a general paradigm shift for ERT-based treatment approaches in which ERTs could be used to effectively treat diseases that significantly affect the central nervous system. Based on our successful Phase I outcomes, Phase II will focus on detailed analyses confirming disease correction within the CNS and visceral organs of GM1 gangliosidosis mice, product scale-up and characterization to support further preclinical assessments and follow-on long-term animal studies on pharmacodynamics, dosing/administration parameters, and amelioration of disease manifestations with larger cohort sizes and gender representation consistent with Rigor and Reproducibility guidance. These studies will support our goal of gaining sufficient data to support a successful application to FDA for IND approval.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = -$180,187 )
2023	2018	BIOSTRATAGIES LC	504 UNIVERSITY LOOP E	JONESBORO	AR	72401	CRAIGHEAD	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	6/20/2023	NON-COMPETING CONTINUATION	-$180,187
														Subtotal = -$180,187

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2018	BIOSTRATAGIES, LC	504 UNIVERSITY LOOP EAST	JONESBORO	AR	72401	CRAIGHEAD	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	8/17/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2018	BIOSTRATAGIES, LC	504 UNIVERSITY LOOP EAST	JONESBORO	AR	72401	CRAIGHEAD	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	8/27/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $1,071,897 )
2018	2018	BIOSTRATAGIES, LC	504 UNIVERSITY LOOP EAST	JONESBORO	AR	72401	CRAIGHEAD	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	8/31/2018	NON-COMPETING CONTINUATION	$1,071,897
														Subtotal = $1,071,897

Issue Date FY: 2017 ( Subtotal = $1,366,586 )
2017	2017	BIOSTRATAGIES, LC	504 UNIVERSITY LOOP EAST	JONESBORO	AR	72401	CRAIGHEAD	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	9/8/2017	COMPETING CONTINUATION	$1,366,586
														Subtotal = $1,366,586

Grand Total All Awards = $2,258,296

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease

Award Number: R44NS084565

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2014

PERIOD OF PERFORMANCE END DATE: 08/31/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer